TSXV:IOT

Stock Analysis Report

Executive Summary

Innovotech Inc. provides solutions to medical, agricultural, and industrial problems caused by microbial biofilms in Canada, the United States and internationally.

Snowflake

Fundamentals

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has Innovotech's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-9.1%

IOT

-2.5%

CA Life Sciences

-0.5%

CA Market


1 Year Return

53.8%

IOT

12.1%

CA Life Sciences

1.1%

CA Market

Return vs Industry: IOT exceeded the Canadian Life Sciences industry which returned 12.1% over the past year.

Return vs Market: IOT exceeded the Canadian Market which returned 1.1% over the past year.


Share holder returns

IOTIndustryMarket
7 Day-9.1%-2.5%-0.5%
30 Day0%-4.5%-1.9%
90 Day66.7%-5.0%-1.6%
1 Year53.8%53.8%12.3%12.1%4.6%1.1%
3 Year566.7%566.7%79.2%77.8%15.8%5.5%
5 Year300.0%300.0%125.3%114.9%26.9%8.6%

Price Volatility Vs. Market

How volatile is Innovotech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Innovotech undervalued based on future cash flows and its price relative to the stock market?

47.87x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Undervalued: Insufficient data to calculate IOT's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate IOT's fair value to establish if it is undervalued.


Price Based on Earnings

PE vs Industry: IOT is unprofitable, so we can't compare its PE Ratio to the Life Sciences industry average.

PE vs Market: IOT is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate IOT's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: IOT is overvalued based on its PB Ratio (47.9x) compared to the XN Life Sciences industry average (4.7x).


Next Steps

Future Growth

How is Innovotech expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

15.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Innovotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Innovotech performed over the past 5 years?

50.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: IOT is unprofitable, but has reduced losses over the past 5 years at a rate of 50.3% per year.

Accelerating Growth: Unable to compare IOT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IOT is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (45%).


Return on Equity

High ROE: IOT has a negative Return on Equity (-5.92%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: IOT is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: IOT is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Innovotech's financial position?


Financial Position Analysis

Short Term Liabilities: IOT's short term assets (CA$186.2K) exceeds its short term liabilities (CA$166.9K)

Long Term Liabilities: IOT has no long term liabilities


Debt to Equity History and Analysis

Debt Level: IOT's debt to equity ratio (132.1%) is considered high

Reducing Debt: IOT had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet

Inventory Level: IOT has a high level of physical assets or inventory.

Debt Coverage by Assets: IOT's debt is covered by short term assets (assets are 1.861820x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IOT has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: IOT has less than a year of cash runway if free cash flow continues to reduce at historical rates of -69.2% each year


Next Steps

Dividend

What is Innovotech's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%6.0%industryaverage0.6%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate IOT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate IOT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if IOT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IOT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IOT's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

What is the CEO of Innovotech's salary, the management and board of directors tenure and is there insider trading?

4.3yrs

Average board tenure


CEO

James Timourian 0

0yrs

Tenure

CA$18,000

Compensation

Dr. James Timourian, Ph.D. has been the President of Innovotech Inc. since January 01, 2014 and serves as its Chief Executive Officer and Secretary. Dr. Timourian has been Mathematician President of Integr ...


Board Age and Tenure

4.3yrs

Average Tenure

Experienced Board: IOT's board of directors are considered experienced (4.3 years average tenure).


Insider Trading

Insider Buying: IOT insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyCA$30007 Oct 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares3,000
Max PriceCA$0.10
BuyCA$2,70003 Oct 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares30,000
Max PriceCA$0.09
BuyCA$4,20002 Oct 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares60,000
Max PriceCA$0.07
BuyCA$1,50001 Oct 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares20,000
Max PriceCA$0.08
BuyCA$1,26030 Sep 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares18,000
Max PriceCA$0.07
BuyCA$1,50025 Sep 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares20,000
Max PriceCA$0.075
BuyCA$67523 Sep 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares8,000
Max PriceCA$0.085
BuyCA$1,90520 Sep 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares22,000
Max PriceCA$0.09
BuyCA$72010 Sep 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares8,000
Max PriceCA$0.09
BuyCA$1,83704 Sep 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares23,000
Max PriceCA$0.08
BuyCA$80029 Aug 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares10,000
Max PriceCA$0.08
BuyCA$3,75022 Aug 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares50,000
Max PriceCA$0.075
BuyCA$8,69931 Jul 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares128,000
Max PriceCA$0.07
BuyCA$10023 Jul 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares2,000
Max PriceCA$0.05
BuyCA$42021 Jun 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares7,000
Max PriceCA$0.06
BuyCA$35013 Jun 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares5,000
Max PriceCA$0.07
BuyCA$1,93011 Jun 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares30,000
Max PriceCA$0.07
BuyCA$12005 Jun 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares2,000
Max PriceCA$0.06
BuyCA$35004 Jun 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares5,000
Max PriceCA$0.07
BuyCA$3,71630 May 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares55,000
Max PriceCA$0.075
BuyCA$35028 May 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares5,000
Max PriceCA$0.07
BuyCA$6,32927 May 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares108,000
Max PriceCA$0.06
BuyCA$1,86924 May 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares30,000
Max PriceCA$0.065
BuyCA$3,82022 May 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares67,000
Max PriceCA$0.06
BuyCA$33001 May 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares6,000
Max PriceCA$0.055
BuyCA$72030 Apr 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares12,000
Max PriceCA$0.06
BuyCA$5,00015 Feb 19
David Tam
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares100,000
Max PriceCA$0.05
BuyCA$42013 Feb 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares7,000
Max PriceCA$0.06
BuyCA$42008 Feb 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares6,000
Max PriceCA$0.07
BuyCA$1,05007 Feb 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares15,000
Max PriceCA$0.07
BuyCA$6006 Feb 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares1,000
Max PriceCA$0.06
BuyCA$5,00019 Jan 19
David Tam
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares100,000
Max PriceCA$0.05
BuyCA$1,90018 Jan 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares38,000
Max PriceCA$0.05
BuyCA$5,00010 Jan 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares100,000
Max PriceCA$0.05
BuyCA$10,00009 Jan 19
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares200,000
Max PriceCA$0.05
BuyCA$15,00014 Dec 18
David Tam
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares300,000
Max PriceCA$0.05
BuyCA$6,25007 Dec 18
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares125,000
Max PriceCA$0.05
BuyCA$70006 Dec 18
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares14,000
Max PriceCA$0.05
BuyCA$25005 Dec 18
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares5,000
Max PriceCA$0.05
BuyCA$5,00004 Dec 18
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares100,000
Max PriceCA$0.05
BuyCA$5,50030 Nov 18
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares100,000
Max PriceCA$0.055
BuyCA$5,50021 Nov 18
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares100,000
Max PriceCA$0.055
BuyCA$5,50019 Nov 18
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares100,000
Max PriceCA$0.055
BuyCA$3,50018 Nov 18
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares70,000
Max PriceCA$0.05
BuyCA$5,00015 Nov 18
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares100,000
Max PriceCA$0.05
BuyCA$10,00014 Nov 18
Alan Savage
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares200,000
Max PriceCA$0.05

Ownership Breakdown


Management Team

  • Alan Savage (76yo)

    CFO & Director

    • Tenure: 2.4yrs
  • James Timourian

    Chairman

    • Tenure: 0yrs
    • Compensation: CA$18.00k
  • Merle Olson

    Scientific Consultant

    • Tenure: 0yrs
  • Amin Omar

    Chief Operating Officer

    • Tenure: 0yrs
    • Compensation: CA$125.38k

Board Members

  • Gerard Tertzakian

    Independent Director

    • Tenure: 18.8yrs
  • Alan Savage (76yo)

    CFO & Director

    • Tenure: 2.4yrs
  • James Timourian

    Chairman

    • Tenure: 0yrs
    • Compensation: CA$18.00k
  • Bernard Grobbelaar

    Independent Director

    • Tenure: 6.5yrs
    • Compensation: CA$68.29k
  • David Tam

    Independent Director

    • Tenure: 1.2yrs
    • Compensation: CA$21.28k
  • Craig Milne

    Independent Director

    • Tenure: 0.3yrs

Company Information

Innovotech Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Innovotech Inc.
  • Ticker: IOT
  • Exchange: TSXV
  • Founded: 2001
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$3.624m
  • Shares outstanding: 36.24m
  • Website: https://www.innovotech.ca

Number of Employees


Location

  • Innovotech Inc.
  • 2011-94 Street
  • Suite L131
  • Edmonton
  • Alberta
  • T6N 1H1
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IOTTSXV (TSX Venture Exchange)YesClass A Common SharesCACADJul 2004

Biography

Innovotech Inc. provides solutions to medical, agricultural, and industrial problems caused by microbial biofilms in Canada, the United States and internationally. The company offers InnovoSIL, an antimicr ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/13 00:30
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)